Expanded 2026 ADA Guidance on SGLT2i in CKD Starting at eGFR ≥20 and combining with a nonsteroidal MRA

Authors

  • Dr Pallavi Mishra english Author

Keywords:

SGLT2 inhibitors, Finerenone (nonsteroidal MRA), Albuminuria (UACR ≥100 mg/g), eGFR threshold ≥20, CONFIDENCE study, Guideline convergence

Abstract

Abstract
The 2026 ADA Standards of Care sharpen and liberalize recommendations for SGLT2 inhibitor use in chronic kidney disease associated with type 2 diabetes. Key updates permit initiation of SGLT2 inhibitors at an eGFR threshold of ≥20 mL/min/1.73 m² and endorse continuation even if eGFR subsequently falls below that level, recognizing preserved cardiorenal benefits throughout advanced CKD. For adults with type 2 diabetes, UACR ≥100 mg/g, and eGFR 30–90 mL/min/1.73 m² on maximal renin–angiotensin system blockade, clinicians may consider simultaneous initiation of an SGLT2 inhibitor and the nonsteroidal mineralocorticoid receptor antagonist finerenone rather than sequential escalation. This recommendation is driven by quantitative evidence from the CONFIDENCE study, in which the combined regimen produced an approximate 52% reduction in albuminuria—roughly 30% greater than either agent alone—providing a mechanistic surrogate for long‑term renal benefit. The KDIGO 2026 draft and CKM guideline converge on similar thresholds and combination strategies, supporting a unified clinical approach. Practical considerations include baseline and serial monitoring of eGFR and potassium, vigilance for hyperkalaemia when adding MRAs, and patient counselling about adverse effects. While individualized judgment remains essential—especially in frail or polypharmacy patients—the updated guidance favors early, aggressive, evidence‑based renoprotective combination therapy to slow progression in albuminuric CKD.

NEWSLETTER 17 Expanded 2026 ADA Guidance on SGLT2i in CKD Starting at eGFR ≥20 and combining with a nonsteroidal MRA Figure 17. Expanded 2026 ADA Guidance on SGLT2i in CKD — mechanism overview (illustrative; labels added for education). The 2026 ADA Standards of Care sharpen the role of SGLT2 inhibitors and nonsteroidal MRAs in chronic kidney disease. In addition to a RAS blocker, simultaneous initiation of an SGLT2 inhibitor and a nonsteroidal MRA (finerenone) can be considered in adults with type 2 diabetes, a UACR ≥100 mg/g, and an eGFR of 30–90 mL/min/1.73 m².1 This endorses a proactive triple approach rather than sequential add-ons in higher-risk patients. The rationale is quantitative. The combination of SGLT2 inhibitor plus finerenone on maximal ACE-inhibitor or ARB therapy produced roughly a 52% reduction in UACR—about 30% better than either drug alone, as shown in the CONFIDENCE study.2 Albuminuria reduction of this magnitude is a strong surrogate for long-term kidney protection. Threshold guidance is now more permissive. SGLT2 inhibitors can be initiated at an eGFR ≥20 mL/min/1.73 m² and continued through kidney failure or below that threshold once started, capturing patients previously considered “too advanced” for initiation.2 The 2025 ADA Standards already recommended SGLT2 inhibitors with demonstrated benefit at eGFR ≥20 for CKD progression and cardiovascular event reduction, and noted that nonsteroidal MRAs do not increase acute kidney injury risk.3 Nephrology guidance is aligned. The KDIGO 2026 draft recommends SGLT2 inhibitors for adults with type 2 diabetes, CKD, and eGFR ≥20 (1A), continuing even if eGFR later falls below 20 unless the patient is intolerant or starts dialysis.4 The shift from sequential to simultaneous therapy is the conceptual heart of the update. Where earlier practice layered drugs one at a time, the 2026 Standards endorse starting an SGLT2 inhibitor and finerenone together on a background of maximal RAS blockade in higher-risk albuminuric patients—front-loading protection during the window when kidneys are deteriorating fastest.1 The roughly 52% UACR reduction seen with the combination in CONFIDENCE, well beyond either agent alone, provides the mechanistic justification for treating aggressively and early.2 All of this dovetails with the 2026 CKM guideline, which likewise makes RAS inhibitors plus SGLT2 inhibitors first-line for CKD with type 2 diabetes or albuminuria, adding a nonsteroidal MRA or GLP-1 therapy if albuminuria persists.5 For clinicians, the convergence of ADA, KDIGO, and CKM guidance around the same thresholds and combinations simplifies decision-making and strengthens the mandate to treat early and combine rationally. References 1. Factsheet: The 2026 ADA Standards of Care — What's new?, DiabetesontheNet, Dec 2025. https://diabetesonthenet.com/diabetes-primary-care/factsheet-2026-ada-standards/ 2. Updates to the ADA Standards of Care 2026 (MCT2D), March 2026. https://www.youtube.com/watch?v=hDjn_2JBGks 3. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025, Diabetes Care. https://diabetesjournals.org/care/article/48/Supplement_1/S239/157554/11-Chronic-Kidney-Disease-and-Risk-Management 4. KDIGO 2026 Diabetes and CKD Guideline Update Public Review Draft, March 2026. https://kdigo.org/wp-content/uploads/2026/03/KDIGO-2026-Diabetes-and-CKD-Guideline-Update-Public-Review-Draft-March-2026.pdf 5. 2026 CKM Guideline — Top Things to Know, professional.heart.org, June 9, 2026. https://professional.heart.org/en/science-news/2026-guideline-for-the-prevention-detection-evaluation-and-management-of-ckm-syndrome/top-things-to-know 6. Beyond Glucose Control: A Comprehensive Review of SGLT2 Inhibitors, Cureus, March 2, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC12952939/

Downloads

Published

2026-07-07

Issue

Vol. 4 No. 17 (2026): Expanded 2026 ADA Guidance on SGLT2i in CKD Starting at eGFR ≥20 and combining with a nonsteroidal MRA

Section

Articles

How to Cite

Expanded 2026 ADA Guidance on SGLT2i in CKD Starting at eGFR ≥20 and combining with a nonsteroidal MRA. (2026). Diabzen, 4(17), 34-35. https://thediabzen.com/index.php/d/article/view/60

Most read articles by the same author(s)